Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Lauren Cherrier"'
Publikováno v:
Frontiers in Transplantation, Vol 3 (2024)
IntroductionRemdesivir (REM) and molnupiravir (MOL) are commonly used to treat lung transplant recipients (LTRs) with COVID-19; however, the clinical efficacy of these medications is yet to be compared. In this retrospective cohort study, we compared
Externí odkaz:
https://doaj.org/article/6b919a3efd61433f97b350690fa4c61d
Autor:
Devika Sindu, MD, Deepika Razia, MD, Katherine Grief, RN, MSN, Lauren Cherrier, MD, Ashraf Omar, MD, Rajat Walia, MD, Sofya Tokman, MD
Publikováno v:
Transplantation Direct, Vol 9, Iss 6, p e1485 (2023)
Background. Lung transplant recipients (LTRs) have an increased risk of COVID-19–related morbidity and mortality. Tixagevimab-cilgavimab (tix-cil) is a long-acting monoclonal antibody combination granted Emergency Use Authorization approval by the
Externí odkaz:
https://doaj.org/article/d25a937585bc4a1fbbf256d2bd1699f1
Publikováno v:
Progress in Transplantation. 33:175-181
Introduction Guidelines recommend the use of direct oral anticoagulation therapy over warfarin for the treatment of venous thromboembolism and atrial fibrillation. However, there is uncertainty and a lack of data supporting the safety and efficacy of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::ec0134927a6d7150be6df333ee8fd556
https://doi.org/10.1177/15269248231164173
https://doi.org/10.1177/15269248231164173
Publikováno v:
Multidisciplinary Respiratory Medicine, Vol 13, Iss 1, Pp 1-5 (2018)
Abstract Background The drug pirfenidone has been shown to slow the progression and decrease mortality of idiopathic pulmonary fibrosis (IPF). Its exact mechanism is unknown, but it likely inhibits pro-fibrotic cytokine transforming growth factor bet
Externí odkaz:
https://doaj.org/article/2858bfdc962e4f6cb5405125766614e8
Autor:
Lauren Cherrier, Razelle Grimes, Rajat Walia, Kellie J Goodlet, Aasya Nasar, Michael D Nailor
Publikováno v:
American Journal of Health-System Pharmacy. 79:338-345
Disclaimer In an effort to expedite the publication of articles , AJHP is posting manuscripts online as soon as possible after acceptance. Accepted manuscripts have been peer-reviewed and copyedited, but are posted online before technical formatting
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::795e0e016a4265ecb31d427424ebd2a0
https://doi.org/10.1093/ajhp/zxab389
https://doi.org/10.1093/ajhp/zxab389
Autor:
Aasya Nasar, Lauren Cherrier, Michael D Nailor, Clover N Truong, Rajat Walia, Kellie J Goodlet
Publikováno v:
Clinical Infectious Diseases. 74:1966-1971
Background Lung transplant recipients residing in the endemic region are vulnerable to severe morbidity and mortality from Coccidioides. As infection risk persists beyond the first posttransplant year, investigations evaluating extended prophylaxis d
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::90824edf6a52c2d13ecfba0baff6c3c7
https://doi.org/10.1093/cid/ciab752
https://doi.org/10.1093/cid/ciab752
Publikováno v:
Transplant Immunology. 75:101703
De novo donor-specific antibodies (DSAs) increase the risk of chronic lung allograft dysfunction (CLAD) in lung transplant recipients (LTRs). Both carfilzomib (CFZ) and rituximab (RTX) lower the mean fluorescent intensity (MFI) of DSAs, but comparati
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8a3fcac67141a9b54dbc73e3a52f9571
https://doi.org/10.1016/j.trim.2022.101703
https://doi.org/10.1016/j.trim.2022.101703
Autor:
Kellie J Goodlet, Lauren Cherrier, Rajat Walia, Aasya Nasar, Michael D Nailor, Clover N Truong
Publikováno v:
Clinical Infectious Diseases. 74:1886-1887
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1c56a11f187541b4045b27908679ce33
https://doi.org/10.1093/cid/ciab879
https://doi.org/10.1093/cid/ciab879
Publikováno v:
Transplant Infectious Disease. 23
Background Lung transplant recipients are at heightened risk for nocardiosis compared to other solid organ transplant recipients, with incidence rates as high as 9% and up to 30% associated mortality. No controlled studies assessing risk factors for
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b6cc43fe7ecee675ba7f6eef3af8b989
https://doi.org/10.1111/tid.13478
https://doi.org/10.1111/tid.13478
Publikováno v:
Multidisciplinary Respiratory Medicine
Background: Cytomegalovirus (CMV) infection is extremely common after lung transplant and can be associated with significant morbidity and mortality. Current practice suggests the use of 900 mg daily of valganciclovir for CMV prophylaxis, but there i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d2e3d35fb0cfa5af26b9765a577f3b0e
https://pubmed.ncbi.nlm.nih.gov/33569173
https://pubmed.ncbi.nlm.nih.gov/33569173